While 2RTs last trial had mixed results, it is only capable for a narrow band of patients and it needs FDA approval, it is potentially a drain on EYEs very limited resources. Increased sales will increase the demand on cashflow - perhaps the SP will stay low for the next few years until the runs are on the board.Perhaps a suitor could snag a bargain at a discount price if it sees value
While 2RTs last trial had mixed results, it is only capable for...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.015(10.3%) |
Mkt cap ! $34.35M | |||
| Open | High | Low | Value | Volume |
| 14.5¢ | 16.0¢ | 14.5¢ | $38.73K | 257.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 84655 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 271846 | 5 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |